sumatriptan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 2543 103628-46-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • GR43175
  • GR 43175
  • sumatriptan
  • sumatriptan succinate
A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
  • Molecular weight: 295.40
  • Formula: C14H21N3O2S
  • CLOGP: 0.74
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 65.20
  • ALOGS: -3.37
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg N
50 mg O
6 mg P
25 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 21.40 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 22 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.68 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 14 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.83 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 28, 1992 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Device deployment issue 733.87 37.06 118 2004 599 2355364
Drug ineffective 713.95 37.06 309 1813 101315 2254648
Drug hypersensitivity 646.47 37.06 233 1889 46410 2309553
Device issue 582.71 37.06 137 1985 5862 2350101
Migraine 389.49 37.06 112 2010 10541 2345422
Needle issue 306.00 37.06 59 2063 935 2355028
Product quality issue 287.38 37.06 89 2033 10740 2345223
Chest discomfort 257.34 37.06 88 2034 14507 2341456
Headache 207.10 37.06 126 1996 80053 2275910
Arteriospasm coronary 188.22 37.06 37 2085 648 2355315
Product substitution issue 187.75 37.06 54 2068 5015 2350948
Nausea 177.62 37.06 130 1992 112059 2243904
Chest pain 162.86 37.06 76 2046 28061 2327902
Dizziness 137.64 37.06 87 2035 58578 2297385
Colitis ischaemic 135.44 37.06 33 2089 1604 2354359
Dyspnoea 125.71 37.06 92 2030 78641 2277322
Paraesthesia 125.59 37.06 59 2063 22029 2333934
Pain 111.72 37.06 78 2044 61779 2294184
Completed suicide 109.80 37.06 53 2069 20981 2334982
IIIrd nerve paresis 107.10 37.06 16 2106 43 2355920
Reversible cerebral vasoconstriction syndrome 106.96 37.06 20 2102 264 2355699
Product complaint 106.25 37.06 34 2088 4504 2351459
Renal infarct 93.92 37.06 18 2104 273 2355690
Exposure during pregnancy 92.22 37.06 50 2072 25169 2330794
Toxicity to various agents 90.35 37.06 54 2068 32700 2323263
Drug interaction 88.09 37.06 51 2071 29112 2326851
Serotonin syndrome 84.81 37.06 27 2095 3513 2352450
Palpitations 84.39 37.06 41 2081 16415 2339548
Vomiting 84.27 37.06 70 2052 71532 2284431
Cerebral vasoconstriction 80.08 37.06 16 2106 304 2355659
Balint's syndrome 79.39 37.06 11 2111 13 2355950
Injection site pain 78.88 37.06 52 2070 37309 2318654
Throat tightness 78.83 37.06 27 2095 4409 2351554
Hypersensitivity 78.57 37.06 44 2078 23549 2332414
Cardiac arrest 75.94 37.06 37 2085 14893 2341070
Malaise 75.19 37.06 59 2063 55526 2300437
Feeling abnormal 67.86 37.06 40 2082 23541 2332422
Device malfunction 66.12 37.06 22 2100 3285 2352678
Condition aggravated 61.41 37.06 42 2080 31937 2324026
Device defective 60.66 37.06 12 2110 216 2355747
Acute myocardial infarction 57.00 37.06 22 2100 5033 2350930
Hypoaesthesia 54.77 37.06 33 2089 20182 2335781
Seizure 53.85 37.06 35 2087 24431 2331532
Lichen planus 52.37 37.06 12 2110 444 2355519
Coronary artery dissection 52.08 37.06 10 2112 153 2355810
Loss of consciousness 51.77 37.06 31 2091 18736 2337227
Angina pectoris 50.89 37.06 19 2103 3968 2351995
Muscle tightness 47.54 37.06 15 2107 1890 2354073
Product administration error 47.46 37.06 18 2104 3925 2352038
Unresponsive to stimuli 47.18 37.06 19 2103 4857 2351106
Urticaria 46.85 37.06 32 2090 24229 2331734
Ischaemic stroke 46.34 37.06 17 2105 3380 2352583
Swollen tongue 45.50 37.06 19 2103 5324 2350639
Burning sensation 44.61 37.06 21 2101 7807 2348156
Vasospasm 44.27 37.06 9 2113 187 2355776
Electrocardiogram ST segment elevation 44.00 37.06 11 2111 592 2355371
Hyperhidrosis 41.29 37.06 25 2097 15397 2340566
Pain in jaw 39.12 37.06 18 2104 6354 2349609
Flushing 39.06 37.06 22 2100 11849 2344114
Neck pain 38.85 37.06 19 2103 7678 2348285
Subclavian artery thrombosis 38.53 37.06 6 2116 23 2355940

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Device deployment issue 141.00 42.23 18 513 34 1746216
Migraine 131.39 42.23 29 502 2282 1743968
Drug ineffective 106.05 42.23 55 476 63746 1682504
Device issue 91.91 42.23 22 509 2460 1743790
Arteriospasm coronary 81.99 42.23 16 515 678 1745572
Needle issue 77.46 42.23 15 516 610 1745640
Completed suicide 68.27 42.23 27 504 16285 1729965
Headache 66.35 42.23 33 498 34343 1711907
Hyperhidrosis 60.46 42.23 23 508 12465 1733785
IIIrd nerve paresis 57.81 42.23 8 523 34 1746216
Serotonin syndrome 55.13 42.23 15 516 2773 1743477
Chest pain 50.09 42.23 23 508 19891 1726359
Foetal exposure during pregnancy 46.83 42.23 16 515 6343 1739907
Drug hypersensitivity 42.83 42.23 19 512 15116 1731134

Pharmacologic Action:

SourceCodeDescription
ATC N02CC01 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist
CHEBI has role CHEBI:50514 vasoconstrictor agent
CHEBI has role CHEBI:35941 serotonergic agonist
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D014662 Vasoconstrictor Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Cluster headache syndrome indication 193031009
Tachyarrhythmia contraindication 6285003
Alcoholism contraindication 7200002
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Hemiplegic migraine contraindication 59292006
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Vascular insufficiency of intestine contraindication 82196007
Epilepsy contraindication 84757009 DOID:1826
Prinzmetal angina contraindication 87343002
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Coronary artery bypass graft contraindication 232717009
Disease of liver contraindication 235856003 DOID:409
Transient ischemic attack contraindication 266257000 DOID:224
Esophageal dysmotility contraindication 266434009 DOID:9192
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Cerebral ischemia contraindication 287731003
Pregnancy, function contraindication 289908002
Thromboembolic disorder contraindication 371039008
Serotonin syndrome contraindication 371089000
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Hypertensive urgency contraindication 443482000
Smokes tobacco daily contraindication 449868002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.23 acidic
pKa2 13.42 acidic
pKa3 8.28 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 8327844 Oct. 3, 2023 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 7975690 Aug. 18, 2025 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 8590530 Sept. 15, 2025 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 10MG BASE TREXIMET CURRAX N021926 May 14, 2015 DISCN TABLET ORAL 7332183 Oct. 2, 2025 ACUTE TREATMENT OF MIGRAINE
EQ 85MG BASE TREXIMET CURRAX N021926 April 15, 2008 RX TABLET ORAL 7332183 Oct. 2, 2025 TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 8440631 May 9, 2026 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 7973058 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8155737 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8470853 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 9427578 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ALSUMA MERIDIAN MEDCL N022377 June 29, 2010 DISCN INJECTABLE SUBCUTANEOUS 7811254 Aug. 26, 2027 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 8875704 April 7, 2028 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8366600 April 21, 2029 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 10603305 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 9610280 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 9974770 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8983594 Nov. 19, 2030 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 9211282 July 19, 2031 ACUTE TREATMENT OF MIGRAINE
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 9327114 Oct. 8, 2032 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10478574 Nov. 4, 2033 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) ZEMBRACE SYMTOUCH UPSHER SMITH LABS N208223 Jan. 28, 2016 RX SOLUTION SUBCUTANEOUS 10537554 Jan. 29, 2036 TREATMENT OF MIGRAINE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 8.26 CHEMBL CHEMBL
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.92 CHEMBL CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 5.60 IUPHAR
5-hydroxytryptamine receptor 1F GPCR Ki 7.59 CHEMBL
5-hydroxytryptamine receptor 5A GPCR IC50 6.30 CHEMBL
5-hydroxytryptamine receptor 3A Ion channel IC50 8.03 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.17 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 8.14 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.42 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.64 CHEMBL
5-hydroxytryptamine receptor 1E GPCR IC50 5.26 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6 IUPHAR
5-hydroxytryptamine receptor 1B GPCR Ki 8.19 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 7.64 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.19 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 7.21 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.35 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 7.70 CHEMBL
5-hydroxytryptamine 1D receptor Unclassified IC50 7.23 CHEMBL
5-hydroxytryptamine receptor 5A Unclassified AGONIST Ki 4.80 IUPHAR
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6.60 IUPHAR
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 5.20 IUPHAR

External reference:

IDSource
4021050 VUID
N0000148514 NUI
C0075632 UMLSCUI
D00451 KEGG_DRUG
322822007 SNOMEDCT_US
4021050 VANDF
004044 NDDF
37418 RXNORM
d03160 MMSL
395892000 SNOMEDCT_US
166806 MMSL
31925 MMSL
8R78F6L9VO UNII
6125 INN_ID
CHEBI:10650 CHEBI
CHEMBL128 ChEMBL_ID
DB00669 DRUGBANK_ID
103628-48-4 SECONDARY_CAS_RN
5358 PUBCHEM_CID
CHEMBL1201150 ChEMBL_ID
D018170 MESH_DESCRIPTOR_UI
54 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0093-2013 INJECTION 4 mg SUBCUTANEOUS ANDA 18 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0093-2014 INJECTION 6 mg SUBCUTANEOUS ANDA 18 sections
SUMATRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 0143-9638 INJECTION 6 mg SUBCUTANEOUS ANDA 17 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0449 INJECTION 6 mg SUBCUTANEOUS NDA 17 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0478 INJECTION 6 mg SUBCUTANEOUS NDA 17 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0479 INJECTION 6 mg SUBCUTANEOUS NDA 17 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0523 SPRAY 20 mg NASAL NDA 17 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0524 SPRAY 5 mg NASAL NDA 17 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0735 TABLET, FILM COATED 25 mg ORAL NDA 17 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0736 TABLET, FILM COATED 50 mg ORAL NDA 17 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0737 TABLET, FILM COATED 100 mg ORAL NDA 17 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0739 INJECTION 4 mg SUBCUTANEOUS NDA 17 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5630 TABLET, FILM COATED 25 mg ORAL ANDA 17 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5631 TABLET, FILM COATED 50 mg ORAL ANDA 17 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5632 TABLET, FILM COATED 100 mg ORAL ANDA 17 sections
Sumatriptan and Naproxen Sodium HUMAN PRESCRIPTION DRUG LABEL 2 0378-8755 TABLET, FILM COATED 85 mg ORAL ANDA 18 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0527-1818 SPRAY 5 mg NASAL ANDA 18 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0527-1859 SPRAY 20 mg NASAL ANDA 18 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3169 INJECTION, SOLUTION 4 mg SUBCUTANEOUS NDA authorized generic 17 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3170 INJECTION, SOLUTION 4 mg SUBCUTANEOUS NDA authorized generic 17 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3172 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA authorized generic 17 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3173 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA authorized generic 17 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3174 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA authorized generic 17 sections
SUMATRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 0781-6523 SPRAY 20 mg NASAL NDA authorized generic 17 sections
SUMATRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 0781-6524 SPRAY 5 mg NASAL NDA authorized generic 17 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 16590-300 TABLET, FILM COATED 100 mg ORAL NDA 13 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-408 TABLET 50 mg ORAL ANDA 16 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-950 TABLET 25 mg ORAL ANDA 16 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 16714-531 TABLET, FILM COATED 25 mg ORAL ANDA 17 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 16714-532 TABLET, FILM COATED 50 mg ORAL ANDA 17 sections